These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

989 related items for PubMed ID: 28861336

  • 1. A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease.
    Demirtaş M, Falcon C, Tucholka A, Gispert JD, Molinuevo JL, Deco G.
    Neuroimage Clin; 2017; 16():343-354. PubMed ID: 28861336
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.
    Skouras S, Falcon C, Tucholka A, Rami L, Sanchez-Valle R, Lladó A, Gispert JD, Molinuevo JL.
    Neuroimage Clin; 2019; 22():101777. PubMed ID: 30913531
    [Abstract] [Full Text] [Related]

  • 3. Intrinsic functional connectivity, CSF biomarker profiles and their relation to cognitive function in mild cognitive impairment.
    Matura S, Köhler J, Reif A, Fusser F, Karakaya T, Scheibe M, Ehret F, Hartmann D, Kang JS, Mayer C, Prvulovic D, Pantel J.
    Acta Neuropsychiatr; 2020 Aug; 32(4):206-213. PubMed ID: 31801648
    [Abstract] [Full Text] [Related]

  • 4. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C, Soldan A, Sloane K, Cai Q, Wang J, Wang MC, Moghekar A, Miller MI, Albert M, BIOCARD Research Team.
    Neuroimage Clin; 2017 Aug; 16():439-446. PubMed ID: 28879085
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.
    Neuroimage Clin; 2015 Aug; 7():598-604. PubMed ID: 25844314
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 10. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.
    J Alzheimers Dis; 2012 Jul 29; 29(1):229-38. PubMed ID: 22232006
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease.
    Teipel SJ, Metzger CD, Brosseron F, Buerger K, Brueggen K, Catak C, Diesing D, Dobisch L, Fliebach K, Franke C, Heneka MT, Kilimann I, Kofler B, Menne F, Peters O, Polcher A, Priller J, Schneider A, Spottke A, Spruth EJ, Thelen M, Thyrian RJ, Wagner M, Düzel E, Jessen F, Dyrba M, DELCODE study group.
    J Alzheimers Dis; 2018 Jul 29; 64(3):801-813. PubMed ID: 29914027
    [Abstract] [Full Text] [Related]

  • 14. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J, Wilson H, Politis M, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2021 Jul 29; 82(2):541-560. PubMed ID: 34057079
    [Abstract] [Full Text] [Related]

  • 15. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D, Moullart V, Schraen S, Devendeville A, Meyer ME, Godefroy O, Alzheimer’s Disease Neuroimaging.
    J Alzheimers Dis; 2016 Jul 29; 51(3):793-800. PubMed ID: 26923012
    [Abstract] [Full Text] [Related]

  • 16. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.
    Canuet L, Pusil S, López ME, Bajo R, Pineda-Pardo JÁ, Cuesta P, Gálvez G, Gaztelu JM, Lourido D, García-Ribas G, Maestú F.
    J Neurosci; 2015 Jul 15; 35(28):10325-30. PubMed ID: 26180207
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S.
    J Alzheimers Dis; 2016 Aug 10; 54(1):383-95. PubMed ID: 27567807
    [Abstract] [Full Text] [Related]

  • 19. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW, Pievani M, Jovicich J, Venturi L, Spitzer P, Vecchio F, Schoenknecht P, Wiltfang J, Redolfi A, Forloni G, Blin O, Irving E, Davis C, Hårdemark HG, Frisoni GB.
    J Alzheimers Dis; 2011 Aug 10; 26 Suppl 3():159-99. PubMed ID: 21971460
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.